CSL Limited announced a $5 billion asset impairment charge and reduced FY26 revenue guidance from $15.8 billion to $15.2 billion
CSL's stock fell to its lowest level since early 2017 following the impairment charge and 4% revenue guidance cut
CSL-Behring broke ground on a $1.5 billion expansion of its Kankakee, Illinois manufacturing facility
The expanded facility is expected to increase production capacity for plasma-derived therapies including Privigen and Hizentra immunoglobulin treatments
The Illinois expansion project is projected to create at least 300 new pharmaceutical jobs and approximately 800 construction and related jobs
The Kankakee expansion facility is expected to become operational by 2031
Illinois state officials offered more than $200 million in tax incentives to secure the project
CSL has invested more than $3 billion in its U.S. operations prior to this expansion